CMOTEC B — Scandinavian ChemoTech AB Share Price
Last trade - 00:00- SEK40.18m
- SEK39.26m
- SEK2.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.64 | ||
| Price to Tang. Book | 11.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -136.1% | ||
| Return on Equity | -168.57% | ||
| Operating Margin | -717.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.56 | 0.13 | 0.05 | 0.47 | 2.82 | 5 | 10 | 38.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.
Directors
- Ingalill Forslund Larsson CHM (65)
- Stefan Frick CEO (43)
- Bertil Persson VRD
- Johan Marnfeldt OTH
- Ann Ohlsson OTH
- Eva Wernersson OTH
- Goran Hellers DRC (72)
- Johan Wennerholm DRC (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 23rd, 2013
- Public Since
- December 6th, 2016
- No. of Employees
- 6
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 17,937,266
- Address
- Medicon Village, Scheelevagen 2, LUND, 223 63
- Web
- https://www.chemotech.se/
- Phone
- Contact
- Stefan Frick
- Auditors
- Mazars SET Revisionsbyra AB
Latest News for CMOTEC B
Upcoming Events for CMOTEC B
Scandinavian ChemoTech AB Annual Shareholders Meeting
Similar to CMOTEC B
Acarix AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Aegirbio AB
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:18 UTC, shares in Scandinavian ChemoTech AB are trading at SEK2.24. This share price information is delayed by 15 minutes.
Shares in Scandinavian ChemoTech AB last closed at SEK2.24 and the price had moved by -51.3% over the past 365 days. In terms of relative price strength the Scandinavian ChemoTech AB share price has underperformed the FTSE Global All Cap Index by -55.39% over the past year.
There is no consensus recommendation for this security.
Scandinavian ChemoTech AB does not currently pay a dividend.
Scandinavian ChemoTech AB does not currently pay a dividend.
Scandinavian ChemoTech AB does not currently pay a dividend.
To buy shares in Scandinavian ChemoTech AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK2.24, shares in Scandinavian ChemoTech AB had a market capitalisation of SEK40.18m.
Here are the trading details for Scandinavian ChemoTech AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: CMOTEC B
Based on an overall assessment of its quality, value and momentum Scandinavian ChemoTech AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Scandinavian ChemoTech AB is SEK2.60. That is 16.07% above the last closing price of SEK2.24.
Analysts covering Scandinavian ChemoTech AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.70 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scandinavian ChemoTech AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -21.68%.
As of the last closing price of SEK2.24, shares in Scandinavian ChemoTech AB were trading -20.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scandinavian ChemoTech AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Scandinavian ChemoTech AB's management team is headed by:
- Ingalill Forslund Larsson - CHM
- Stefan Frick - CEO
- Bertil Persson - VRD
- Johan Marnfeldt - OTH
- Ann Ohlsson - OTH
- Eva Wernersson - OTH
- Goran Hellers - DRC
- Johan Wennerholm - DRC